To investigate the association between the methylenetetrahydrofolate Aims: dehydrogenase 1 (MTHFD1) polymorphism rs 2236225 (c.1958G>A) and susceptibility to non-syndromic cleft of the lip and/or palate (NSCL/P).
Introduction
Cleft of the lip and/or palate (CL/P) is one of the most common facial malformations [1] [2] [3] and a societal burden, affecting the patient ability to eat and speak and influencing social integration 4 . Nonsyndromic CL/P, accounting for about 70% of CL/P, is considered closely related to genetic and environmental factors 5 . Recent studies suggested that using folic acid could reduce the rates of oral clefts 6, 7 and single nucleotide polymorphisms of some genes such as MTHFR 8, 9 , MTR 40 and MTRR involved in the metabolism of folic acid have been associated to high risk of NSCL/P 8, 9 . Methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), a key gene associated with three sequential enzymatic reactions in the metabolism of folic acid, might play a potential role in the risk of NSCL/P, especially the polymorphism rs2236225 (c.1958G>A) 10 . Indeed, different observations that linked the polymorphism rs2236225 to the risk of NSCL/P have been reported 11, 12 . The suggestion of a link between rs2236225 polymorphism and susceptibility to NSCL/P might be result of the limitations in sample size, different ethnic populations and other environmental factors. Therefore, we conducted a systematic review and meta-analysis of eligible case-control studies to reveal a more precise connection between the MTHFD1 polymorphism rs2236225 and the risk of NSCL/P.
Materials and methods
Identification of studies A systematic search based on the principle of evidence-based medicine 13 was performed in PubMed, Web of Science, Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI) and WanFang Database. The final update was made on April 5th, 2015. In line with our knowledge background, the Medical Subject Headings (MESH) terms in PubMed and the known aliases of the genes of interests in the National Center of Biotechnology Information (NCBI), the following terms were used for searching: "cleft lip OR cleft palate OR CLP OR CL/P OR oral facial cleft OR OFC" AND "methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 OR methenyltetrahydrofolate cyclohydrolase formyltetrahydrofolate synthetase OR MTHFD1 OR MTHFD", which were slightly adjusted to optimize search results (Table S1 ; PubMed). We didn't limit the search depending on publication types, data and language. Of course, the review of the published literature was examined carefully and manual search was conducted to avoid missing potential data. Two of the authors (Huaxiang Zhao and Mengqi Zhang) were in charge of the search independently and a third author (Jieni Zhang) conducted a random inspection.
Inclusion and exclusion criteria
Researches included in our systematic review and meta-analysis meet the following criteria: (1) evaluating the association between the NSCL/P and MTHFD1 polymorphism rs2236225, (2) focusing on humans, (3) case-control studies. Exclusion criteria were: (1) no association between NSCL/P and MTFHD1, (2) not focusing on humans but animal models or in vitro studies, (3) duplication of previous researches, (4) not original literature such as reviews, meta-analyses, comments and editorials.
Data collection
Data from eligible studies were extracted by two independent researchers (Huaxiang Zhao and Mengqi Zhang) in accordance with the inclusion and exclusion criteria. In case of any discrepancies, the third chief author (Feng Chen) would make a further investigation or bring it into a group-discussion. A special table was used for collecting information from the selected articles and the following entries were recorded: authors (year), country, location of geography, subjects, methods for genotyping, sample size of cases/controls, descriptions of samples rolled in the study, P for HWE (Hardy-Weinberg equilibrium) of control group, whether included in the meta-analysis or not.
Methodological quality assessment
A methodological quality assessment adapted from previous studies [14] [15] [16] was carried on included studies (Table S2) . Cases, source of controls, sample sizes and Hardy-Weinberg equilibrium (HWE) were considered as important aspects in this systematic review. It is not a widely-used standard so its efficiency is not certain. The result does not include the judgments but the standard can be a reference for the certainty of conclusion.
Statistical analysis
The PRISMA checklist (Supplementary material S3) was used as a protocol in our meta-analysis 17 . Odd ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between the susceptibility to NSCL/P and MTHFD1. Five genetic models were used in the process of pooling the OR and 95% CIs: allelic comparison (A versus G), heterozygote model (AG versus GG), homozygote model (AA versus GG), dominant model (AA + AG versus GG), recessive model (AA versus AG + GG). The significance of the pooled effects was determined by Z-test with P value less than 0.05. The Q-statistic and the I 2 test were used to evaluated; P < 0.05 in Q statistic or I 2 > 50% 18, 19 , would indicate a significant heterogeneity. When P > 0.05 in Q statistic or I 2 < 50%, the fixed pooling model (Mantel-Haenszel) was conducted; if not, the
Amendments from Version 1
The following modifications have been made in the newest version: 1. All the gene acronyms were re-written italics; 2. Table S2 was an assessment standard for included articles but the assessment scores were not included in our article, we explained this matter in Materials and methods --Methodological quality assessment; 3. Page 6, Figure 1 , Eligibility section, the number of full-text articles excluded with reasons were corrected with 5; 4. The publication bias analysis when < 10 articles is not statistically resolved (see Egers's paper), so a comment about this issue was added in Results --Sensitivity analysis and publication bias and the fourth paragraph in Discussion 5. In order to reduce the repeat content in the first two paragraph of Discussion and Introduction, we deleted several sentences in the Discussion; 6. In the third paragraph of Discussion, a description of the controversial conclusions of included studies was made to make the discussion more interesting. 7. Based on our result, we deeply explained our conclusion and put out suggestion about sample taking in future studies in the last paragraph. [20] [21] [22] . The studies with disequilibrium of HWE among control group were added into a supplementary meta-analysis as described previously 23 . Meanwhile, as for the studies included but not carried into the meta-analysis, to achieve a qualitative analysis we adopted a method described by others 24 .
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Results were considered significant when P < 0.05. Stata 12.0 (Stata Corp, College Station, TX, USA) was used for the analysis.
Results
Data retrieval
A total of 251 articles resulted from the search described above (PubMed: 86, Web of Science: 8, Google Scholar: 135, Cochrane Library: 0, CNKI: 18, Wanfang: 4). After being imported into EndNote X6 software (Thomson Corporation, Stamford), a screening process was conducted among 102 articles-that is, duplicates were removed using the 'Discard Duplicates' function as well as by handwork. Following paper selection by two independent researchers, 15 studies were then thoroughly reviewed. Of these, five studies were excluded, among which two had no control groups 25, 26 , one no relation to MTFHD1 27 , and the other two presented data previously published 28, 29 . Finally, 10 studies that met the criteria were included in the systematic review (Table 1) 10-12,30-36 and mathematic data from eight studies were used for reference to carry out the metaanalysis [10] [11] [12] [31] [32] [33] 35, 36 . The selection process is shown in Figure 1 .
Study characteristics
Eventually, all 10 studies containing 6216 samples (2959 cases and 3257 controls) were analyzed in our review. The characteristics of every study can be seen in Table 1 . To summarize briefly, there were four studies from European groups, four from Asian groups and two from South American groups, among which two studies focused on the genotype of patients' mothers only, four on children' s genotype only and four on both of them. PCR-restriction fragment length polymorphism (PCR-RFLP) was the major method of genotyping, while other techniques had been used as well.
Association between MTHFD1 polymorphism rs2236225 (c.1958G>A) and NSCL/P susceptibility The association between MTHFD1 polymorphism rs2236225 (c.1958G>A) and NSCL/P susceptibility was analyzed through a meta-analysis and qualitative analysis. In the meta-analysis, since significant heterogeneity had been identified by Q-test and I 2 statistic in every genetic model, the random effect models were used. Overall, a significant association was not found in any genetic model (A versus G: OR = 1.02, 95% CI 0.86-1.21, P H = 0.010, Figure 2 ; AG versus GG: OR = 0.97, 95% CI 0.75-1.26, P H = 0.019, Figure 3A ; AA versus GG: OR = 1.07, 95% CI 0.70-1.65, P H = 0.005, Figure 3B ; AA + AG versus GG: OR = 1.00, 95% CI 0.76-1.31, P H = 0.006, Figure 3C ; AA versus AG + GG: OR = 1.05, 95% CI 0.71-1.53, P H = 0.014, Figure 3D ). On the other hand, no association was found in the genotypes of children, mothers or fathers in the qualitative analysis 30, 34 .
Next we conducted the subgroup analysis using allelic A versus G model according to the location of geography and subjects (mothers or children). It turned out that there was no significant difference between Asian (OR = 1.03, 95% CI 0.75-1.40, P H = 0.003) or non-Asian population (OR = 1.06, 95% CI 0.86-1.30, P H = 0.118). However, a higher degree of heterogeneity was observed in the Asian countries compared to non-Asian countries ( Figure 4A ). A similar result was observed in the subgroup analysis between mothers and children. The heterogeneity was much higher in the children group (OR = 0.99, 95% CI 0.72-1.36, P H = 0.001) than in the mothers' group (OR = 1.11, 95% CI 0.98-1.27, P H = 0.630), while no significant difference was observed in both groups ( Figure 4B ).
Sensitivity analysis and publication bias
To access the influence of each individual study on the pooled ORs, a sensitivity analysis was performed by omitting each study at a time. The results of sensitivity suggests that no individual study affects the pooled ORs of the associations between MTHFD1 polymorphism rs2236225 (c.1958G>A) and NSCL/P risk under allelic model ( Figure 5 ).
We used the Begg's funnel plot and Egger's regression test (both used the allelic A versus G model) to estimate the publication bias.
Our results indicate that there is no significant publication bias both in the symmetry of Begg's funnel plot (P = 0.711, Figure 6 ) and Egger's regression test (P = 0.746). But due to the sample size (the total number of included article is less than 10), statistical analyses may not describe the publication bias precisely. The test reliability is in doubt.
Discussion
CL/P is one of the most common facial malformations, affecting approximately 1.7/1000 people around the world with ethnic and geographic variation 1 . Approximately 70% of CL/P cases are considered to be non-syndromic 37, 38 , and their susceptibility has been linked to the expression of various candidate genes through twin studies, familial clustering studies and genome-wide studies 39 . Recent studies suggest that using folic acid could reduce the rates of oral clefts 6, 7 and genes involved in the metabolish of folic acid have been identified MTHFD1, a crucial gene associated with three sequential enzymatic reactions among 5,10-methylenetetrahydrofolate, 5,10-methenyltetrahydrofolate, 10-formyltetrahydrofolate, tetrahydrofolate, might play a potential role in NSCL/P 10 . However, controversial results about the MTHFD1 polymorphism rs2236225 (c.1958G>A) have been reported in different articles 10, 12 .
In this systematic review, 10 independent case-control studies were included (eight studies for meta-analysis and two studies qualitatively analyzed) containing 6216 samples (2959 cases and 3257 controls). In all of the included 8 studies for meta-analysis, 7 did not show significant difference between the case and control groups. 1 study reported that the case group showed closer relationship with MTHFD1 polymorphisms rs 2236225 (c.1958G>A). After the over-all analysis we concluded the comprehensive effect. All the eligible studies of meta-analysis and qualitative analysis showed no significant association of MTHFD1 rs2236225 to the risk of (2013) Yuan (2013) Subtotal (I−squared = 78.6%, p = 0.001) Zhao et al (2013) Yuan ( NSCL/P, whether in the whole analysis of five model (A versus G, AG versus GG, AA versus GG, AA + AG versus GG, AA versus AG + GG) or in the subgroup of subjects (mothers or children) and the location of geography (non-Asian countries or Asian countries). Meanwhile, high heterogeneity was observed, which might be the reason for the genetic drift and natural selection among different ethnic groups
42
. Also, small sample size of different studies might be a possible reason for the disparate results. Our findings suggest that the MTHFD1 polymorphism rs2236225 (c.1958G>A) might not be an appropriate biomarker in predicting the susceptibility of an individual to NSCL/P. Some limitations of this systematic review and meta-analysis should be noted. Firstly, the choice of retrospective studies has its own limitations, as we may encounter selection bias and influence the results of our analysis 43 . However, a bigger size of cohort study cannot be conducted easily because of the relatively low morbidity 44 . Secondly, only 10 studies were included in our review, a small sample size that might not provide sufficient evidence to estimate the connections between the MTHFD1 polymorphisms and the risk of NSCL/P. Thirdly, the publication bias cannot be effectively analyzed because of the limited amount of included study.
NSCL/P is also associated with gene-gene and gene-environment interactions 45 . Although no correlation was observed between MTFHD1 polymorphism rs2236225 (c.1958G>A) and the risk of NSCL/P, in view of MTFHD1 gene's key role in folic acid metabolism, we cannot draw a definite conclusion that there is no association between MTFHD1 and NSCL/P's susceptibility. The use of larger sample size studies, different techniques and considering gene-gene or gene-environment interactions should be explored in future investigations. What is more, the gene samples from mother were too scarce to be representative and to explain our results. We do recommend more samples from parents in the future studies, which is significant for the early stage diagnose, as the current technology can only diagnose CLP in the midterm even later in the pregnancy.
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Actually the Discussion is an overview of the article, which includes and further explains the content above. While in avoidance of repetition we modified and simplified the first and second paragraph of the Discussion.
Two of our included studies only analyzed the maternal genotype, one study reported the mother and children genotype and three took samples from children and their parents. The gene samples from mother were too scarce to be representative and to explain our results. We do recommend more samples from parents in the future studies, which is significant for the early stage diagnose, as the current technology can only diagnose CLP in the midterm even later in the pregnancy.
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